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Background
Cells with “stem cell properties”, denominated cancer stem
cells (CSCs), have been recently isolated from a variety of
human solid tumors. These cells have been considered as
responsible of resistance to standard therapy such as che-
motherapy and radiotherapy. Immunotherapy, due to its
specificity and lack of toxicity can represent a promising
approach to target cancer stem cells.
Thus, it is relevant to assess whether CSCs isolated
from solid tumors, can be exploited as source of anti-
gens to elicit T cell-mediated immune responses and to
design novel immunotherapeutic protocols for tumors.
Results
In our group CSCs from glioblastoma multiforme (GBM)
and colorectal cancer (CRC) have been isolated from
tumor biopsies and have been biologically characterized.
Moreover, a detailed immunological characterization of
these CSCs has been performed leading to the identifica-
tion of a low immunogenic profile with negative immu-
noregulatory properties (Di Tomaso et al, 2010).
We found that both CSCs and the differentiated coun-
terpart of tumors (FBS tumor cells) expressed immune
modulatory molecules, such as CTLA-4, PD-1, PDL-1
and B7H3, with, in some cases, higher levels in CSCS vs.
FBS tumor cells. Furthermore, a differential gene signa-
ture that was confirmed at the protein level for some
immunological-related molecules was also found for CSC
and FBS lines. A candidate negative immunoregulatory
molecule is represented by the indoleamine 2,3-dioxy-
genase (IDO), a molecule implicated in the generation of
immune tolerance. By RT-PCR we detected the preferen-
tial increase of the mRNA of this molecule in CSCs vs
FBS tumor cells following IFN-ϒ treatment. The func-
tional activity of IDO determining, by a colorimetric
assay, IDO-mediated tryptophan catabolism in culture
supernatants was also found to be preferentially asso-
ciated with CSCs.
Of note, CRC CICs expressed higher levels of IL-4 as
compared with FBS tumor cell pairs. CIC-associated IL-4
could mediate, by cell-to cell contact, the inhibition of
proliferation of T cells following the co-culture with
autologous CIC.
The neutralization in functional assays of at least one
of the negative modulatory signals mentioned above, led
to the modulation of both the type and the quality of
tumor-specific T cell immune responses.
Micro-RNA (miRNA) profile, including miRNA with
immunoregulatory functions, has been identified to be
specifically associated with CSCs vs. FBS tumor cell pairs
as well.
Conclusions
Multiple mechanisms of immunoregulation that are
exploited by CSCs to escape from T cell-mediated surveil-
lance have been identified. These results may allow design-
ing more effective immunotherapy protocols to target
CSCs from GBM and/or CRC patients.
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